Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Moderate Buy” by Analysts
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% Following Weak Earnings
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
What made Corvus stock double on Tuesday and is it sustainable?
Corvus Stock Spikes On Heels Of Strong Eczema Study Results
Why Small Biotech Stock Corvus Pharma Just Launched To An Eight-Year High
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Critical Analysis: Tenaya Therapeutics (NASDAQ:TNYA) vs. Corvus Pharmaceuticals (NASDAQ:CRVS)
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
3 Penny Stocks Wall Street Sees With 243% Upside
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Why Is Corvus Pharmaceuticals Stock Soaring On Friday?
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors